A durable partial response to OPB-111077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, has already been observed in a DLBCL patient in a recent Phase I study in advanced cancers (42). This evidence concerns the gene STAT3 and diffuse large B-cell lymphoma.